Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Sep 2018: Trial started, NCT03683433
  2. 25 Sep 2018: Trial registered, NCT03683433

The trials

NCT03683433: Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

State
Under way
Phase
Phase 2
People
50 planned
Started
18 Sep 2018
Primary completion
20 Sep 2027
Arms
Treatment (azacitidine, enasidenib mesylate)
Results
None posted
  1. 18 Sep 2018: Trial started
  2. 25 Sep 2018: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.